ZAI LAB LIMITED (ZLAB) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 443.75M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 195.54M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $443.75M | $195.54M | (m) |
| 2026-03-31 | (m) | $447.09M | $190.38M | (m) |
| 2025-12-31 | (m) | $457.18M | $190.52M | (m) |
| 2025-09-30 | (m) | $438.61M | $170.00M | (m) |
| 2025-06-30 | (m) | $425.09M | $159.81M | (m) |
| 2025-03-31 | (m) | $416.12M | $151.95M | (m) |
| 2024-12-31 | (m) | $397.61M | $147.12M | (m) |
| 2024-09-30 | (m) | $354.93M | (m) | (m) |
| 2024-06-30 | (m) | $322.31M | (m) | (m) |
| 2024-03-31 | (m) | $291.07M | (m) | (m) |
| 2023-12-31 | (m) | $266.72M | (m) | (m) |
| 2023-09-30 | (m) | $262.93M | (m) | (m) |
| 2023-06-30 | (m) | $250.66M | (m) | (m) |
| 2023-03-31 | (m) | $229.37M | (m) | (m) |
| 2022-12-31 | (m) | $212.67M | (m) | (m) |
| 2022-09-30 | (m) | $194.60M | (m) | (m) |
| 2022-06-30 | (m) | $180.74M | (m) | (m) |
| 2022-03-31 | (m) | $170.10M | (m) | (m) |
| 2021-12-31 | (m) | $144.10M | (m) | (m) |
| 2021-09-30 | (m) | $115.23M | (m) | (m) |
| 2021-06-30 | (m) | $86.78M | (m) | (m) |
| 2021-03-31 | (m) | $60.84M | (m) | (m) |
| 2020-12-31 | (m) | $48.96M | (m) | (m) |
| 2020-09-30 | (m) | $38.51M | (m) | (m) |
| 2020-06-30 | (m) | $28.78M | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $12.98M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2018-12-31 | $85.86K | $129.45K | (m) | 66.33% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |